We Americans have been a patient people as of the last several months, hoping and praying that an end to this coronavirus nightmare would be coming soon.
Not only are an incredible number of us being personally affected by this horrific disease, but the need for social distancing has shuttered countless businesses from coast to coast, and shoved a great many Americans into the unemployment line.
Now, with just a few weeks left in the year from hell, Pfizer looks poised to swoop in and save us…with the FDA’s approval, of course.
In the Phase 3 study involving more than 43,000 volunteers, half received the experimental vaccine and half got a placebo. Participants received two shots, spaced 21 days apart.
And, as if to place an exclamation point at the end of this good-feeling story:
The companies said the vaccine’s efficacy held up across gender, race, ethnicity and various ages. In people older than 65, a group at elevated risk from COVID-19, the efficacy was 94%.
Become an insider!
Sign up for our free email newsletter, and we'll make sure to keep you in the loop.